Skip to the page

Data / Federal rules / 2026-13139

Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis

The Food and Drug Administration published this final rule in the Federal Register on June 30, 2026. It took effect on June 30, 2026.

SpecStream is the live web data engine for teams and agents. It reads every rule and proposed rule in the Federal Register each morning, and this page is that reading. Name your industry once and new rules, comment deadlines and effective dates arrive in your sheet, CRM, Slack or agent as they are published.

What the agency says

The Food and Drug Administration (FDA) is classifying the skin patch for treatment of hyperhidrosis into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the skin patch for treatment of hyperhidrosis. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

Key facts

Document number
2026-13139
Type
Final rule
Action
Final amendment; final order
Agency
Health and Human Services Department; Food and Drug Administration
Published
June 30, 2026
Takes effect
June 30, 2026
Dates
This order is effective June 30, 2026. The classification was applicable on April 7, 2023.
Docket
Docket No. FDA-2026-N-6711
Code of Federal Regulations
21 CFR 878
Topics
Medical devices
Pages
3

The document on federalregister.gov PDF

Other documents from the Food and Drug Administration

Everything from the Food and Drug Administration · Rules on medical devices · Published in June 2026

Read from the Federal Register API, last updated 2026-10-23. The document on federalregister.gov is the official record; dates and dockets can change through later corrections. Free to reuse with credit to SpecStream under CC BY 4.0.